id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-353551-un4jw7aw	Margoni, Monica	Natalizumab safety in paediatric-onset multiple sclerosis at the time of SARS-Cov-2 pandemic	2020-10-12		.txt	text/plain	836	49	56	title: Natalizumab safety in paediatric-onset multiple sclerosis at the time of SARS-Cov-2 pandemic The authors, considering the impact of MS on brain atrophy and the high risk POMS have to develop cognitive impairment and evolve in the secondary progressive disease phase, recommend to keep in mind that MS in children/teens is a severe, highly active form of disease, and suggest the early use of highly effective second-line disease modifying drugs rather than the first-line injectable ones. May these drugs expose POMS to a greater risk of SARS-Cov-2 infection as well as to a symptomatic and potentially more severe COVID-19 or to longterm autoimmune severe adverse events? NTZ treatment does not seem not to expose POMS to a higher risk of SARS-Cov-2 infection. No evidence of disease activity including cognition (NEDA-3 plus) in naive pediatric multiple sclerosis patients treated with natalizumab Disease Modifying Therapies and COVID-19 Severity in Multiple Sclerosis	./cache/cord-353551-un4jw7aw.txt	./txt/cord-353551-un4jw7aw.txt